CytoMed Therapeutics Issues Press Release

Ticker: GDTC · Form: 6-K · Filed: Oct 3, 2024 · CIK: 1873093

Cytomed Therapeutics LTD 6-K Filing Summary
FieldDetail
CompanyCytomed Therapeutics LTD (GDTC)
Form Type6-K
Filed DateOct 3, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: press-release, filing-update

TL;DR

CytoMed dropped a press release on Oct 3rd, details TBD.

AI Summary

On October 3, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details regarding the content of this press release or any specific financial figures or events.

Why It Matters

This filing indicates that CytoMed Therapeutics has made a public announcement, which could contain material information for investors. However, the specific details are not yet available in this report.

Risk Assessment

Risk Level: low — The filing is a routine 6-K report announcing a press release without providing specific material information or financial updates.

Key Players & Entities

FAQ

What was the subject of the press release issued by CytoMed Therapeutics on October 3, 2024?

The filing states that CytoMed Therapeutics issued a press release on October 3, 2024, but the content of the press release is not detailed within this Form 6-K.

What is the principal executive office address for CytoMed Therapeutics Limited?

The principal executive office address for CytoMed Therapeutics Limited is 1 Commonwealth Lane #08-22, Singapore 149544.

What is CytoMed Therapeutics Limited's SIC code?

CytoMed Therapeutics Limited's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

When was CytoMed Therapeutics Limited formerly known as CytoMed Therapeutics Pte. Ltd.?

The company changed its name from CytoMed Therapeutics Pte. Ltd. on July 16, 2021.

Is CytoMed Therapeutics Limited required to file annual reports under Form 20-F or Form 40-F?

CytoMed Therapeutics Limited is indicated to file annual reports under cover of Form 20-F.

Filing Stats: 333 words · 1 min read · ~1 pages · Grade level 14.7 · Accepted 2024-10-03 07:00:19

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited Date: October 3, 2024 By: /s/ CHOO Chee Kong CHOO Chee Kong Director and Chairman

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing